// App-Quantinova.ai

: Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC.

Researchers

Presenter

  • Christopher Sweeney

Principal Investigators

  • Ryon Graf

  • David Fabrizio

  • Kobe Yuen

  • Matthew J. Wongchenko

  • Pratyush Gupta

  • Priti Hegde

  • Geoffrey R. Oxnard

  • Thomas Powles

Medical Centers

  • Barts Heart Centre, London, UK

  • South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia

  • Foundation Medicine, Inc, Cambridge, MA

  • CellMax Life, Sunnyvale, CA

  • Roche/Genentech, South San Francisco, CA

  • Genentech, Inc., South San Francisico, CA

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

Locations

  • United Kingdom

  • Australia

  • United States

Companies

  • Foundation Medicine,

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating DNA

Drug/Treatment

  • CB-7598

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • III

Study Id's

  • NCT03016312

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved